PRODUCT LITERATURE

Mometasone furoate in the management of asthma: a review

---

Inhaled corticosteroids (ICS) have proven to be the most effective and essential therapy for the treatment of bronchial asthma. The 2007 National Asthma Education and Prevention Program guidelines recommend ICS as preferred therapy for patients with mild to severe persistent asthma. Mometasone furoate (MF) is a relatively new ICS agent with high affi nity for the glucocorticoid receptor. It is approved in the US for maintenance treatment of asthma for patients 4 years of age and older. It has been shown to be well tolerated with no signifi cant adverse side effects observed in clinical trials and post-marketing surveillance.
The effi cacy of mometasone furoate has been established in large, well-designed studies. In patients with persistent asthma previously treated either with short-acting beta-agonists alone or twice-daily maintenance therapy with ICS, once-daily MF has been shown to be superior to placebo in improving lung function, symptom control, and quality of life; and has shown comparable effi cacy compared with budesonide, beclomethasone, and fl uticasone. Twice-daily
dosing with MF has been demonstrated to successfully allow for reduction or elimination of oral corticosteroids in severe asthmatics.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

LITERATURE

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Asthma
Modexa
Mometasone furoate nasal spray

Specific Detail Info

Therapeutics and Clinical Risk Management 2008:4(6) 1201–1208

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment